Late-Stage Trials Pose Challenge As FDA Molds Adaptive Design Guidance
Executive Summary
The work group developing FDA's guidance on adaptive clinical trial design is still trying to figure out the complex issues associated with late-stage studies, the Center for Drug Evaluation and Research's "town hall" discussion at the Drug Information Association annual meeting in Atlanta revealed
You may also be interested in...
EMEA Looking At Limited Use Of Adaptive Design In Late-Stage Trials
Adaptive designs are "a contradiction to the confirmatory nature" of Phase III clinical trials, EMEA's Committee for Medicinal Products for Human Use says in a reflection paper
EMEA Looking At Limited Use Of Adaptive Design In Late-Stage Trials
Adaptive designs are "a contradiction to the confirmatory nature" of Phase III clinical trials, EMEA's Committee for Medicinal Products for Human Use says in a reflection paper
FDA Is Waiting On Internal Analysis Of Avandia Cardiovascular Safety Signal
FDA is not taking immediate regulatory action on an observed cardiovascular signal for GlaxoSmithKline's Avandia, as the agency feels the current labeling is sufficient until its own analysis of emerging safety data for the type 2 diabetes therapy is completed